Kirk Kee1,2,3, John Dixon4, Jonathan Shaw5, Elena Vulikh5, Markus Schlaich6,7, David M Kaye8, Paul Zimmet2,5, Matthew T Naughton2,3. 1. Department Respiratory and Sleep Medicine, The Royal Melbourne Hospital, Melbourne, Australia. 2. Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia. 3. Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Australia. 4. Clinical Obesity Research, Baker Heart and Diabetes Institute, Melbourne, Australia. 5. Clinical Diabetes and Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Australia. 6. Neurovascular, Hypertension and Kidney Disease Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia. 7. Dobney Hypertension Centre, School of Medicine and Pharmacology - Royal Perth Hospital Unit, University of Western Australia and Departments of Cardiology and Nephrology, Royal Perth, Australia. 8. Heart Failure Research, Baker Heart and Diabetes Institute, Melbourne, Australia.
Abstract
STUDY OBJECTIVES: Sleep apnea is associated with adverse health outcomes. Despite being an important comorbidity in obesity, type 2 diabetes, heart failure, and resistant hypertension, it is underdiagnosed in these patient groups. An inexpensive and readily accessible sleep apnea screening tool would help address this problem. We sought to compare three commonly used screening tools. METHODS: We recruited 812 patients who had not previously been investigated for sleep apnea from our institution's diabetes (n = 512), obesity (n = 129), resistant hypertension (n = 74) and heart failure (n = 43) clinics. Patients completed three frequently used sleep apnea screening questionnaires (STOP-BANG, Berlin, and OSA50). A total of 758 patients had a valid (> 4 hours' duration) level 3 home sleep study. Studies were reported by a sleep physician and were deemed positive if they recorded a respiratory event index (REI) ≥ 15 events/h. RESULTS: The 758 patients with valid sleep studies were age 59 ± 11 years and 63% were male. A total of 38% of patients had a positive test. The respective sensitivities and specificities of the screening questionnaires at the recommended screening thresholds (REI ≥ 15 events/h) were STOP-BANG ≥ 3 (95% and 19%), STOP-BANG ≥ 5 (60% and 69%), Berlin (75% and 38%), and OSA50 (88% and 21%). We identified six independent predictors (age, sex, body mass index, neck circumference, snoring ≥ 3 days per week, observed apnea ≥ 3 days per week). However, combining these factors was no better than the STOP-BANG in predicting sleep apnea. All patients with a STOP-BANG < 3 had an REI < 30 events/h. CONCLUSIONS: There is a high prevalence of undiagnosed symptomatic sleep apnea in high-risk patient groups. The STOP-BANG questionnaire appeared superior, though all questionnaires had significant limitations. Incorporation of STOP-BANG ≥ 3 in this high-risk population might reduce the need for sleep testing in a resource-constrained setting.
STUDY OBJECTIVES:Sleep apnea is associated with adverse health outcomes. Despite being an important comorbidity in obesity, type 2 diabetes, heart failure, and resistant hypertension, it is underdiagnosed in these patient groups. An inexpensive and readily accessible sleep apnea screening tool would help address this problem. We sought to compare three commonly used screening tools. METHODS: We recruited 812 patients who had not previously been investigated for sleep apnea from our institution's diabetes (n = 512), obesity (n = 129), resistant hypertension (n = 74) and heart failure (n = 43) clinics. Patients completed three frequently used sleep apnea screening questionnaires (STOP-BANG, Berlin, and OSA50). A total of 758 patients had a valid (> 4 hours' duration) level 3 home sleep study. Studies were reported by a sleep physician and were deemed positive if they recorded a respiratory event index (REI) ≥ 15 events/h. RESULTS: The 758 patients with valid sleep studies were age 59 ± 11 years and 63% were male. A total of 38% of patients had a positive test. The respective sensitivities and specificities of the screening questionnaires at the recommended screening thresholds (REI ≥ 15 events/h) were STOP-BANG ≥ 3 (95% and 19%), STOP-BANG ≥ 5 (60% and 69%), Berlin (75% and 38%), and OSA50 (88% and 21%). We identified six independent predictors (age, sex, body mass index, neck circumference, snoring ≥ 3 days per week, observed apnea ≥ 3 days per week). However, combining these factors was no better than the STOP-BANG in predicting sleep apnea. All patients with a STOP-BANG < 3 had an REI < 30 events/h. CONCLUSIONS: There is a high prevalence of undiagnosed symptomatic sleep apnea in high-risk patient groups. The STOP-BANG questionnaire appeared superior, though all questionnaires had significant limitations. Incorporation of STOP-BANG ≥ 3 in this high-risk population might reduce the need for sleep testing in a resource-constrained setting.
Authors: R Doug McEvoy; Nick A Antic; Emma Heeley; Yuanming Luo; Qiong Ou; Xilong Zhang; Olga Mediano; Rui Chen; Luciano F Drager; Zhihong Liu; Guofang Chen; Baoliang Du; Nigel McArdle; Sutapa Mukherjee; Manjari Tripathi; Laurent Billot; Qiang Li; Geraldo Lorenzi-Filho; Ferran Barbe; Susan Redline; Jiguang Wang; Hisatomi Arima; Bruce Neal; David P White; Ron R Grunstein; Nanshan Zhong; Craig S Anderson Journal: N Engl J Med Date: 2016-08-28 Impact factor: 91.245
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Athanasia Pataka; Euphemia Daskalopoulou; George Kalamaras; Katalin Fekete Passa; Parakevi Argyropoulou Journal: Sleep Med Date: 2014-04-20 Impact factor: 3.492
Authors: Naresh M Punjabi; Brian S Caffo; James L Goodwin; Daniel J Gottlieb; Anne B Newman; George T O'Connor; David M Rapoport; Susan Redline; Helaine E Resnick; John A Robbins; Eyal Shahar; Mark L Unruh; Jonathan M Samet Journal: PLoS Med Date: 2009-08-18 Impact factor: 11.069